Shares of plastic surgery clinics rose 17%. How is this related to the GLP-1 trend?

Shares of AirSculpt Technologies, a small-cap operator of plastic surgery clinics, surged nearly 17% on the Nasdaq on August 11. The boom in GLP-1 weight-loss drugs could bring the company more than $100 million in the long term, as rapid weight loss leaves some patients in need of skin tightening procedures, said CEO Yogi Jashnani.

Patients taking GLP-1-based anti-obesity drugs could become a significant source of future growth for the company and generate more than $100 million for it in the long term, said CEO Yogi Jashnani at a conference hosted by investment bank Canaccord Genuity on August 11 (as reported by MarketBeat). By comparison, AirSculpt’s revenue for all of 2025 totaled $151.8 million, down nearly 16%.

People who lose weight over a period of 6 to 18 months may experience sagging skin, which creates a demand for procedures to remove excess skin and perform a lift, Jashnani explained.

To advance this area of focus, AirSculpt has, in particular, entered into a partnership with Tiger Aesthetics, a manufacturer of dermal fillers and breast expanders. The partnership involves the development of alloClae—a product based on donor fat designed to restore body volume. The procedure is intended for patients who do not have enough of their own fat for a traditional fat transfer.

"We've seen stability for the second consecutive quarter following many periods of decline," Jashnani said during the conference. According to him, this is reflected in the increase in the number of procedures. For the April–June period, the number of procedures at comparable medical centers increased by 1% year-over-year, AirSculpt reported on August 10.

At the same time, the company reported a 32.5% decline in quarterly revenue to $42.9 million and an 83% increase in net loss to $1.1 million. It also reaffirmed its full-year revenue forecast in the range of $151–157 million. In the worst-case scenario, this represents a 0.6% decline from 2025 levels; in the best-case scenario, it represents growth of just over 3%.

At the same time, AirSculpt lowered its forecast for adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization): It had previously expected it to be in the range of $15–17 million, but now expects it to be $12–14 million. Investors were not pleased: On August 10, the company’s stock price plummeted 45% to $2.75, its lowest level since late March.

AirSculpt shares have two “hold” ratings from Wall Street analysts and one “buy” rating. The average price target of $4.50 implies upside potential of nearly 41% relative to the closing price on August 11.